RxDoctor Payments Data

Megan Brands, NP

Family · Boise, IDNPI 1760003438

Payments from drug & device makers

$610in general payments, 2019–2025

Across 21 payments — averaging $29.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$195
  • AbbVie$108
  • Coloplast$85
  • Novartis$47
  • Novo Nordisk$31
  • Sanofi Pasteur Inc.$27
  • plus $116 from 6 others

What the payments were for

  • Food & beverage$610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$610 in reported general payments places this provider in the 60th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$34,667
Medicare patients
165
Services billed
431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$31,140
MounjaroTirzepatide15$21,578
Atorvastatin Calcium229$1,816
Sumatriptan Succinate15$1,665
Levothyroxine Sodium188$1,593
Pregabalin14$1,585
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,158
Losartan Potassium122$1,120
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide55$1,091
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$925
Venlafaxine Hcl ErVenlafaxine Hcl30$834
Gabapentin53$800
Rosuvastatin Calcium77$785
Olmesartan Medoxomil39$733
Lisinopril106$718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$31,14030 claims
AbbVieSynthroid$108$61121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 809 family providers in Idaho.

Other family in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →